Showing results (171-180 of 185) with videos related to

Sort By:
Pageof 19
Haematologica|January 12, 2023
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS studyFrancesca R Mauro, Irene Della Starza, Monica Messina, et al.
European Journal of Haematology|December 30, 2020
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia casesFortunato Morabito, Giovanni Tripepi, Giovanni Del Poeta, et al.
Leukemia|September 19, 2025
Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC studyAndrea Visentin, Enrico Gaffo, Moritz Fürstenau, et al.
Leukemia|April 24, 2025
ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarkerBirna Thorvaldsdottir, Larry Mansouri, Lesley-Ann Sutton, et al.
Cancer Medicine|September 24, 2020
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US studyAntonio Cuneo, Anthony R Mato, Gian Matteo Rigolin, et al.
Haematologica|August 3, 2019
Biological and clinical implications of <i>BIRC3</i> mutations in chronic lymphocytic leukemiaFary Diop, Riccardo Moia, Chiara Favini, et al.
Hematological Oncology|July 20, 2022
Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COVPatrizia Zappasodi, Chiara Cattaneo, Virginia Valeria Ferretti, et al.
Blood Advances|October 13, 2021
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort studyCarlo Visco, Luigi Marcheselli, Roberto Mina, et al.
Leukemia|December 24, 2022
Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONYLarry Mansouri, Birna Thorvaldsdottir, Lesley-Ann Sutton, et al.
The Lancet. Haematology|August 18, 2020
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort studyFrancesco Passamonti, Chiara Cattaneo, Luca Arcaini, et al.
Pageof 19